Karyopharm Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Karyopharm Therapeutics Inc. (KPTI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Karyopharm Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.93M, a 49.02% decline year-over-year.
- Karyopharm Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.01M, a 15.53% decline year-over-year.
- Karyopharm Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $3.90M, a 1.01% increase year-over-year.
- Karyopharm Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.80M, a 32.97% decline year-over-year.
- Karyopharm Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $14.05M, a 23.75% decline from fiscal 2024.
- Karyopharm Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $18.43M, a 15.12% decline from fiscal 2023.
- Karyopharm Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $21.71M, a 38.67% decline from fiscal 2022.
- Karyopharm Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $35.40M, a 18.86% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.93M 10-Q · filed 2026-08-13 | $4.94M 10-Q · filed 2026-08-13 | $8.84M derived: sum of 3 quarters · filed 2026-08-13 | $11.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.01M 10-Q · filed 2026-05-14 | $6.91M derived: sum of 2 quarters · filed 2026-05-14 | $9.71M derived: sum of 3 quarters · filed 2026-05-14 | $13.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $6.71M derived: sum of 2 quarters · filed 2026-02-13 | $10.49M derived: sum of 3 quarters · filed 2026-08-13 | $14.05M 10-K · filed 2026-02-13 |
| 2025-09-30 | $2.80M 10-Q · filed 2025-11-03 | $6.59M derived: sum of 2 quarters · filed 2026-08-13 | $10.15M 10-Q · filed 2025-11-03 | $14.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.78M 10-Q · filed 2026-08-13 | $7.34M 10-Q · filed 2026-08-13 | $11.21M derived: sum of 3 quarters · filed 2026-08-13 | $15.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $3.56M 10-Q · filed 2026-05-14 | $7.42M derived: sum of 2 quarters · filed 2026-05-14 | $11.61M derived: sum of 3 quarters · filed 2026-05-14 | $17.02M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $8.05M derived: sum of 2 quarters · filed 2026-02-13 | $13.46M derived: sum of 3 quarters · filed 2026-02-13 | $18.43M 10-K · filed 2026-02-13 |
| 2024-09-30 | $4.18M 10-Q · filed 2025-11-03 | $9.59M derived: sum of 2 quarters · filed 2025-11-03 | $14.56M 10-Q · filed 2025-11-03 | $19.74M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $5.41M 10-Q · filed 2025-08-11 | $10.38M 10-Q · filed 2025-08-11 | $15.56M derived: sum of 3 quarters · filed 2026-02-13 | $20.64M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $4.97M 10-Q · filed 2025-05-12 | $10.15M derived: sum of 2 quarters · filed 2026-02-13 | $15.23M derived: sum of 3 quarters · filed 2026-02-13 | $21.29M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $10.26M derived: sum of 2 quarters · filed 2026-02-13 | $16.32M derived: sum of 3 quarters · filed 2026-02-13 | $21.71M 10-K · filed 2026-02-13 |
| 2023-09-30 | $5.08M 10-Q · filed 2024-11-05 | $11.14M derived: sum of 2 quarters · filed 2024-11-05 | $16.53M 10-Q · filed 2024-11-05 | $22.70M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $6.06M 10-Q · filed 2024-08-06 | $11.45M 10-Q · filed 2024-08-06 | $17.62M derived: sum of 3 quarters · filed 2025-02-19 | $24.42M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $5.39M 10-Q · filed 2024-05-08 | $11.56M derived: sum of 2 quarters · filed 2025-02-19 | $18.36M derived: sum of 3 quarters · filed 2025-02-19 | $33.45M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $12.97M derived: sum of 2 quarters · filed 2025-02-19 | $28.06M derived: sum of 3 quarters · filed 2025-02-19 | $35.40M 10-K · filed 2025-02-19 |
| 2022-09-30 | $6.80M 10-Q · filed 2023-11-02 | $21.89M derived: sum of 2 quarters · filed 2023-11-02 | $29.23M 10-Q · filed 2023-11-02 | $36.09M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $15.09M 10-Q · filed 2023-08-02 | $22.43M 10-Q · filed 2023-08-02 | $29.30M derived: sum of 3 quarters · filed 2024-02-29 | $36.72M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $7.34M 10-Q · filed 2023-05-04 | $14.21M derived: sum of 2 quarters · filed 2024-02-29 | $21.63M derived: sum of 3 quarters · filed 2024-02-29 | $29.76M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $6.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $14.29M derived: sum of 2 quarters · filed 2024-02-29 | $22.42M derived: sum of 3 quarters · filed 2024-02-29 | $29.78M 10-K · filed 2024-02-29 |
| 2021-09-30 | $7.42M 10-Q · filed 2022-11-03 | $15.55M derived: sum of 2 quarters · filed 2022-11-03 | $22.91M 10-Q · filed 2022-11-03 | $29.23M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $8.13M 10-Q · filed 2022-08-04 | $15.49M 10-Q · filed 2022-08-04 | $21.81M derived: sum of 3 quarters · filed 2023-02-17 | $28.32M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $7.36M 10-Q · filed 2022-05-05 | $13.67M derived: sum of 2 quarters · filed 2023-02-17 | $20.19M derived: sum of 3 quarters · filed 2023-02-17 | $26.61M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $6.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $12.83M derived: sum of 2 quarters · filed 2023-02-17 | $19.25M derived: sum of 3 quarters · filed 2023-02-17 | $24.41M 10-K · filed 2023-02-17 |
| 2020-09-30 | $6.51M 10-Q · filed 2021-11-03 | $12.94M derived: sum of 2 quarters · filed 2021-11-03 | $18.09M 10-Q · filed 2021-11-03 | $21.64M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $6.43M 10-Q · filed 2021-08-05 | $11.58M 10-Q · filed 2021-08-05 | $15.13M derived: sum of 3 quarters · filed 2022-03-01 | $18.85M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $5.15M 10-Q · filed 2021-05-04 | $8.70M derived: sum of 2 quarters · filed 2022-03-01 | $12.42M derived: sum of 3 quarters · filed 2022-03-01 | $16.54M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.27M derived: sum of 2 quarters · filed 2022-03-01 | $11.38M derived: sum of 3 quarters · filed 2022-03-01 | $15.29M 10-K · filed 2022-03-01 |
| 2019-09-30 | $3.72M 10-Q · filed 2020-11-02 | $7.83M derived: sum of 2 quarters · filed 2020-11-02 | $11.74M 10-Q · filed 2020-11-02 | $15.64M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $4.12M 10-Q · filed 2020-08-04 | $8.02M 10-Q · filed 2020-08-04 | $11.92M derived: sum of 3 quarters · filed 2021-02-24 | $16.70M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $3.91M 10-Q · filed 2020-05-05 | $7.80M derived: sum of 2 quarters · filed 2021-02-24 | $12.58M derived: sum of 3 quarters · filed 2021-02-24 | $17.02M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $8.67M derived: sum of 2 quarters · filed 2021-02-24 | $13.11M derived: sum of 3 quarters · filed 2021-02-24 | $17.27M 10-K · filed 2021-02-24 |
| 2018-09-30 | $4.78M 10-Q · filed 2019-11-04 | $9.21M derived: sum of 2 quarters · filed 2019-11-04 | $13.38M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $4.44M 10-Q · filed 2019-08-07 | $8.60M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $4.16M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $20.41M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $22.28M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $17.06M 10-K · filed 2018-03-15 | |||
| 2014-12-31 | $14.24M 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $3.79M 10-K · filed 2016-03-15 | |||
| 2012-12-31 | $653.00K 10-K · filed 2015-03-13 | |||
| 2011-12-31 | $24.00K 10-K · filed 2014-03-21 | |||
| 2010-12-31 | $46.00K 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |